Erschienen in:
12.09.2023 | Research
Naples score: a novel prognostic biomarker for breast cancer patients undergoing neoadjuvant chemotherapy
verfasst von:
Yuting Xiu, Cong Jiang, Qinghua Huang, Xiao Yu, Kun Qiao, Danping Wu, Xiaotian Yang, Shiyuan Zhang, Xiangshi Lu, Yuanxi Huang
Erschienen in:
Journal of Cancer Research and Clinical Oncology
|
Ausgabe 17/2023
Einloggen, um Zugang zu erhalten
Abstract
Background and purpose
The Naples Score (NPS) is a novel prognostic indicator that has been used in various cancers, but its potential in breast malignant tumor patients receiving neoadjuvant chemotherapy (NAC) has not been discovered. This study aimed to investigate the relationship between NPS and overall survival (OS) and disease-free survival (DFS) in breast cancer patients.
Methods
A total of 217 breast cancer patients undergoing NAC were incorporated into this retrospectively research. K–M survival curves and log-rank tests are used to determine OS and DFS. Cox regression model was used to evaluate the relationship between NPS and OS and DFS. Nomogram was developed based on the results of multivariate Cox regression analysis. Prognostic models were internally validated using bootstrapping and the consistency index (C-index).
Results
Age group was correlated with NPS (p < 0.05). Low and moderate Naples risk patients had higher 5-year OS and DFS rates than high risk Naples patients (93.8% vs. 75.4% vs. 60.0%; X2 = 9.2, P = 0.01; 82.4% vs 64.5% vs 43.7%; X2 = 7.4, P = 0.024; respectively). The nomogram based on demonstrated good performance in predicting OS and DFS (AUC = 0.728, 0.630; respectively).
Conclusions
In breast cancer patients who have undergone NAC, NPS is a novel prognostic indicator. NPS combined with clinicopathological features showed good predictive ability, and its performance was better than that of traditional pathological TNM staging.